

### ASCIA ANNUAL CONFERENCE



ASCIA 2023 Conference - highly successful hybrid event, with over 700 delegates (72% in-person) in Sydney, 5-8 September 2023.

Read more [here](#)

### ASCIA WEBSITE



From July 2022 to 30 June 2023 the ASCIA website attracted more than 2.9 million pageviews, 1.9 million sessions (visits) and 1.5 million users (unique visitors).

Read more [here](#)

### ASCIA COMMUNICATIONS



More than 700 ASCIA members and 5,100 community subscribers were informed about allergy and immunology updates via monthly [ASCIA e-newsletters](#) and 45 [ASCIA information updates](#).

### AIFA RESEARCH GRANTS



More than \$700,000 has to be awarded in [AIFA research grants](#) to 34 research projects since the program commenced in 2015.

### ASCIA E-TRAINING COURSES



ASCIA continues to provide [world leading online training](#), with over 1 million registrations since March 2010. ASCIA anaphylaxis e-training courses were updated in 2023 with new versions of [ASCIA Action Plans and First Aid Plans](#).

### ADVOCACY & COLLABORATIONS



ASCIA lodged [17 submissions](#) from July 2022 to June 2023.

ASCIA also advocates through [collaborations](#) with over 30 other groups.

### IMMUNODEFICIENCY STRATEGY



An implementation meeting for the ASCIA Immunodeficiency Strategy for Australia and New Zealand was held on 29 April 2022, and the first goal has been achieved. Read more [here](#)

### NATIONAL ALLERGY COUNCIL



[ASCIA Reports](#) have been developed as part of National Allergy Council projects, including e-training feedback reports, for the first time since the courses were introduced in 2010. Other progress is reported [here](#).

### PRIORITIES FOR 2023-2024

ASCIA will implement a [new Strategic Plan](#) which is based on the following three strategic areas:

**1. ASCIA Member Services** - including website updates, communications, AIFA grants, sustainability and advocacy.

**2. ASCIA Professional Development** - including the ASCIA 2024 Conference and other meetings.

**3. ASCIA Collaborations** - including implementation of the ASCIA Immunodeficiency Strategy and National Allergy Council projects, as well as links with NACE, CFAR and other research, professional and patient/carers organisations.